Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 14 de 14
2.
Ann Rheum Dis ; 68(6): 873-8, 2009 Jun.
Article En | MEDLINE | ID: mdl-18625625

OBJECTIVES: Wegener's granulomatosis (WG) is a systemic vasculitis characterised by relapsing and remitting disease activity. Immunosuppressive drugs are used to control disease, but increase susceptibility to infection. Therefore, influenza vaccination should be considered in WG patients. This study was performed to assess the immunogenicity of influenza vaccination in WG patients. METHODS: A randomised, controlled trial was performed in WG patients with quiescent disease, defined as a Birmingham vasculitis activity score (BVAS) less than 2. Patients were randomly assigned to receive influenza vaccination (n = 49) or to participate as controls (n = 23). In addition, healthy controls (n = 49) were vaccinated. At entry and at 1 and 3-4 months after entry, antibody responses to vaccination were determined. Furthermore, disease activity was measured (BVAS), adverse effects were recorded and antineutrophil cytoplasmic autoantibody (ANCA) titres were determined. RESULTS: WG patients achieved high seroprotection rates to all three influenza strains, comparable with healthy controls. Only the A/H1N1 strain patients had a lower seroconversion rate (p = 0.002) and geometric mean titre (p = 0.037) than controls. After 1 month, one control and one vaccinated WG patient had developed active disease. At 3-4 months, two additional control patients had developed active disease compared with none of the vaccinated patients (p = 0.099). Vaccination did not influence ANCA titres. Adverse effects did not differ between patients and healthy controls. CONCLUSIONS: Influenza vaccination in WG patients with quiescent disease induced a sufficient antibody response. TRIAL REGISTRATION NUMBER: NTR1130.


Antibodies, Viral/blood , Granulomatosis with Polyangiitis/immunology , Influenza A Virus, H1N1 Subtype/immunology , Influenza Vaccines/immunology , Orthomyxoviridae/immunology , Adult , Aged , Aged, 80 and over , Antibodies, Antineutrophil Cytoplasmic/blood , Case-Control Studies , Chi-Square Distribution , Female , Granulomatosis with Polyangiitis/drug therapy , Humans , Immunosuppressive Agents/therapeutic use , Influenza Vaccines/administration & dosage , Influenza Vaccines/adverse effects , Influenza, Human/prevention & control , Male , Middle Aged , Prospective Studies , Treatment Outcome , Vasculitis/immunology
3.
J Viral Hepat ; 14(2): 140-6, 2007 Feb.
Article En | MEDLINE | ID: mdl-17244254

Hepatitis E virus (HEV) infections in developed countries are recognized as an imported disease related to travel to endemic regions. However, increasing evidence suggests that HEV infection may also occur in the developed countries and that swine may act as a possible reservoir. To investigate the indigenous transmission of HEV in the Netherlands, sera from 50 blood donors and 1027 sera from patients with acute hepatitis were screened with an ELISA for HEV-specific IgG and IgM. Because the Netherlands is considered a nonendemic region, all positive ELISA results were confirmed by immunoblot to exclude false-positive results. Evidence of recent HEV infection was detected in 0% of the blood donors and 4.4% of the cases, based on combined positive IgM and IgG responses. The serodiagnosis was confirmed by a positive polymerase chain reaction (PCR) in 24 patients with hepatitis (2.3% overall, 51% of confirmed IgM+/IgG+ cases). IgG antibodies alone were detected in 4.2% of patients. We found related sequences to virus strains detected in Dutch pigs (genotype 3, 91-97% homology) in 89% of PCR-confirmed HEV patients. The detection of unique swine-like HEV sequences in 16 indigenous hepatitis patients without a recent travel history suggests that HEV is endemic in the Netherlands. We recommend including HEV tests in unexplained acute hepatitis patients, despite their travel history.


Hepatitis E virus/isolation & purification , Hepatitis E/epidemiology , Animals , Base Sequence , Blood Donors , Hepatitis E/blood , Hepatitis E virus/genetics , Hepatitis E virus/immunology , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Netherlands/epidemiology , Phylogeny , Polymerase Chain Reaction/methods , Seroepidemiologic Studies , Swine
4.
Ned Tijdschr Geneeskd ; 150(16): 909-12, 2006 Apr 22.
Article Nl | MEDLINE | ID: mdl-16686092

A male infant born vaginally after a gestation period of 25 4/7 weeks with a birth weight of 875 g underwent surgical correction for oesophageal atresia with a distal tracheo-oesophageal fistula. Postoperative complications included seam leakage, mediastinitis with sepsis, transient elevated diaphragm, recurrent fistula and seam stenosis. Persistent ductus arteriosus was closed surgically. The further course of disease was characterised by periventricular haemorrhage, recurrent infections, bronchopulmonary dysplasia and retinopathy. Anaemia caused by the premature birth and frequent blood sampling necessitated multiple transfusions of filtered, Cytomegalovirus(CMV)-free erythrocyte concentrate. At the age of 3 months, the patient developed cholestatic jaundice that was attributed to a CMV infection contracted through breast milk. The patient recovered spontaneously. At the age of 2 years, the patient had mildly impaired psychomotor development. Reactivation of CMV during lactation is common in CMV-seropositive women. This carries a high risk of transmission of the virus through breast milk, especially for extremely premature neonates. In these infants, an early acquired postnatal CMV infection may lead to serious disorders.


Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/transmission , Infectious Disease Transmission, Vertical , Milk, Human/virology , Pregnancy Complications, Infectious/diagnosis , Adult , Child Development/physiology , Child, Preschool , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/complications , Female , Humans , Infant , Infant, Newborn , Infant, Premature , Lactation , Male , Pregnancy , Risk Assessment
5.
Am J Perinatol ; 23(1): 59-61, 2006 Jan.
Article En | MEDLINE | ID: mdl-16450275

Nonpolio enterovirus (NPEV) infections are known to cause a wide range of illnesses in the neonatal period. In most cases, NPEV is presumed to be contracted during birth. Intrauterine NPEV infections occur infrequently. A case of intrauterine echovirus 11 infection with pneumonia, persistent pulmonary hypertension of the newborn, and purpura fulminans is presented.


Echovirus Infections/complications , Enterovirus B, Human , Fetal Diseases/virology , Hypertension, Pulmonary/virology , Pneumonia, Viral/virology , Echovirus Infections/physiopathology , Echovirus Infections/therapy , Fatal Outcome , Female , Humans , Hypertension, Pulmonary/physiopathology , Hypertension, Pulmonary/therapy , IgA Vasculitis/virology , Infant, Newborn , Pregnancy , Pregnancy Complications, Infectious/physiopathology
6.
Ann Rheum Dis ; 65(7): 913-8, 2006 Jul.
Article En | MEDLINE | ID: mdl-16322083

OBJECTIVE: to assess the safety and efficacy of influenza vaccination in patients with systemic lupus erythematosus (SLE), and to evaluate the influence of immunosuppressive drugs on the immune response. METHODS: SLE patients (n=56) and healthy controls (n=18) were studied. All patients had quiescent disease (SLE disease activity indexor=40 against A/H3N2 (p=0.030) compared with the other patient groups. CONCLUSIONS: Influenza vaccination in SLE patients with quiescent disease is safe but is less effective than in controls. Use of azathioprine was associated with a trend to decreased vaccination efficacy.


Influenza Vaccines/administration & dosage , Lupus Erythematosus, Systemic/immunology , Adult , Aged , Antibodies, Viral/blood , Azathioprine/therapeutic use , Case-Control Studies , Female , Hemagglutination Inhibition Tests , Humans , Hydroxychloroquine/therapeutic use , Immunosuppressive Agents/therapeutic use , Influenza Vaccines/adverse effects , Influenza Vaccines/immunology , Lupus Erythematosus, Systemic/drug therapy , Male , Middle Aged , Orthomyxoviridae/immunology , Prednisone/therapeutic use , Statistics, Nonparametric , Vaccination/adverse effects
8.
J Clin Virol ; 33(2): 145-9, 2005 Jun.
Article En | MEDLINE | ID: mdl-15911430

BACKGROUND: Hepatitis E virus (HEV) is the major etiologic agent of enterically transmitted viral hepatitis in much of the developing world. Evidence provided in recent years shows that HEV is also prevalent in very low numbers in non-endemic countries. Recently, a cluster of three patients with acute hepatitis E but no history of travel to endemic countries was discovered in the geographical area provided with service by the Public Health Laboratory Groningen and Drenthe, The Netherlands. OBJECTIVE: This lead to the question whether hepatitis E is a cause of unexplained hepatitis in this district. STUDY DESIGN: The prevalence of anti-HEV IgG and IgM among 209 patients with clinical signs of hepatitis, negative test for hepatitis A-C, no history of foreign travel and no other cause of hepatocellular damage was compared with a matched control group of 209 individuals. RESULTS: We found a significant difference in seroprevalence between the two groups for IgG anti-HEV as determined with the Abbot HEV EIA (6.2% versus 0.5%); however this difference could not be confirmed with the Genelabs Diagnostics HEV IgG ELISA (6.7% versus 3.8%). For confirmed cases of IgM anti-HEV we also detected a significant difference between the two groups (3.3% versus 0.5%). Remarkably, the combination of IgG and IgM anti-HEV was only found among hepatitis patients. CONCLUSION: This study provides evidence of locally acquired hepatitis E in The Netherlands. Therefore, in cases of unexplained acute hepatitis, the diagnosis of hepatitis E should be considered even in the absence of foreign travel.


Hepatitis E virus/immunology , Hepatitis E/epidemiology , Adolescent , Adult , Age Distribution , Aged , Antibodies, Viral/blood , Child , Child, Preschool , Female , Hepatitis E/diagnosis , Humans , Immunoenzyme Techniques , Immunoglobulin G/blood , Immunoglobulin M/blood , Infant , Male , Middle Aged , Netherlands
9.
Clin Diagn Lab Immunol ; 5(1): 114-7, 1998 Jan.
Article En | MEDLINE | ID: mdl-9455891

A neutralization enzyme immunoassay (N-EIA) was used to determine the neutralizing serum antibody titers to influenza A/Taiwan/1/86 (H1N1) and Beijing/353/89 (H3N2) viruses after vaccination of 51 human immunodeficiency virus (HIV) type 1-infected individuals and 10 healthy noninfected controls against influenza virus infection. Overall, the N-EIA titers correlated well with the hemagglutination-inhibition (HAI) titers that were observed in the same samples in a previous study (F. P. Kroon, J. T. van Dissel, J. C. de Jong, and R. van Furth, AIDS 8:469-476,1994). The N-EIA appeared to be more sensitive than the HAI test. Significantly more fourfold or higher rises in N-EIA titer and higher mean N-EIA titers occurred in HIV-infected individuals with > or =200 CD4+ cells per microl than in those with <200 CD4+ cells per microl.


HIV Infections/prevention & control , Influenza A virus/immunology , Influenza Vaccines/therapeutic use , Vaccination , Adult , Antibodies, Viral/blood , Antibody Formation , Antibody-Dependent Enhancement , Data Interpretation, Statistical , Female , Hemagglutination Inhibition Tests , Humans , Immunoenzyme Techniques , Male , Methods , Middle Aged , Neutralization Tests , Time Factors
10.
Vaccine ; 15(9): 1039-44, 1997 Jun.
Article En | MEDLINE | ID: mdl-9261954

The influence of various adjuvants on the development of influenza virus neutralizing antibodies and distribution of anti-influenza virus IgG isotypes after immunization of mice with influenza A (H3N2) subunit vaccine was investigated. Serum titres of influenza virus neutralizing antibodies and titres of influenza specific IgG isotypes were determined by a neutralization enzyme immunoassay (N-EIA) and a cell-associated antigen enzyme immunoassay (CA-EIA), respectively. Serum antibody titres as measured by the two tests correlated highly (r = 0.82; P < 0.001). N-EIA titres were enhanced by 38- and 34-fold, when L180.5/RaLPS and FCA, respectively, were administered with 1 microgram of vaccine. The adjuvants Q-VAC, L180.5 [W/O/W], L180.5 alone and Montanide ISA 740 were only moderately or not effective in enhancing the immune response to the 1 microgram dose of vaccine. The Q-VAC and L180.5/RaLPS adjuvants favoured IgG2a and IgG2b isotype responses to influenza compared to the other adjuvants. We suggest that N-EIA and CA-EIA may be valuable tools to monitor the effects of adjuvants on the neutralizing antibody and antibody isotype responses after influenza vaccination.


Adjuvants, Immunologic/pharmacology , Antibodies, Viral/biosynthesis , Antibodies, Viral/immunology , Antigens, Viral/immunology , Immunoglobulin Isotypes/biosynthesis , Influenza A virus/immunology , Influenza Vaccines/immunology , Orthomyxoviridae Infections/immunology , Animals , Antibodies, Viral/blood , Antibodies, Viral/drug effects , Binding, Competitive/immunology , Cells, Cultured , Female , Haplorhini , Immunoenzyme Techniques , Immunoglobulin G/biosynthesis , Immunoglobulin G/blood , Immunoglobulin G/classification , Immunoglobulin Isotypes/blood , Influenza A virus/chemistry , Kidney/cytology , Mice , Mice, Inbred BALB C , Neutralization Tests
11.
Eur J Immunol ; 27(4): 886-90, 1997 Apr.
Article En | MEDLINE | ID: mdl-9130640

Surfactant protein A (SP-A) and surfactant protein D (SP-D) are collectins, and both proteins were shown to interact with influenza A virus and alveolar macrophages. However, it is not known whether SP-A and SP-D can serve as opsonins for the phagocytosis of influenza A virus by alveolar macrophages. In the present study, we investigated the opsonic activities of SP-A and SP-D for phagocytosis of fluorescein isothiocyanate (FITC)-labeled influenza A (H3N2) virus by rat alveolar macrophages using flow cytometry. SP-A enhanced the association of the virus with macrophages in a dose-dependent manner, reaching a maximum at an SP-A concentration of 60 microg/ml. An approximate threefold increase in association of influenza A virus with alveolar macrophages in the presence of SP-A over control incubations which contained no SP-A was observed. Half of the total cell-associated fluorescence could be quenched as demonstrated using the extracellular quenching dye trypan blue. These results indicate that SP-A mediates internalization of FITC-labeled influenza A (H3N2) virus by alveolar macrophages. Removal of the carbohydrate moiety of SP-A by N-glycosidase F treatment or cleavage of its sialic acid residues by neuraminidase abolished the enhancement of the phagocytosis of FITC-labeled influenza A virus by alveolar macrophages. Mannan, a mannose homopolysaccharide known to bind to the carbohydrate-binding domain of SP-A, did not affect the SP-A-mediated phagocytosis of FITC-labeled influenza by alveolar macrophages. In contrast, SP-D neither enhanced the association of FITC-labeled influenza A virus with alveolar macrophages nor affected the opsonic activity of SP-A for FITC-labeled influenza A (H3N2) virus at the SP-D concentrations tested. It is concluded that SP-A acts via its sialic acid residues as an opsonin in the phagocytosis of influenza A virus by alveolar macrophages.


Carrier Proteins/immunology , Glycoproteins/immunology , Influenza A virus/immunology , Macrophages, Alveolar/immunology , Opsonin Proteins/physiology , Phagocytosis/drug effects , Proteolipids/immunology , Pulmonary Surfactants/immunology , Animals , Carrier Proteins/physiology , Fluorescein-5-isothiocyanate , Glycoproteins/physiology , Humans , Male , Oligosaccharides/pharmacology , Proteolipids/physiology , Pulmonary Surfactant-Associated Protein A , Pulmonary Surfactant-Associated Protein D , Pulmonary Surfactant-Associated Proteins , Pulmonary Surfactants/physiology , Rats , Rats, Wistar
12.
J Infect Dis ; 171(2): 335-41, 1995 Feb.
Article En | MEDLINE | ID: mdl-7844369

The interaction of pulmonary surfactant protein A (SP-A) with influenza A H1N1 and H3N2 viruses was investigated. SP-A is a sialated C type lectin with affinity for mannose residues. Flow cytometry showed that binding of fluorescein isothiocyanate (FITC)-labeled SP-A to H3N2 virus-infected cells was specific and time- and concentration-dependent. Oligosaccharides did not affect the binding of FITC-SP-A to the infected cells. Preincubation of H1N1 and H3N2 with SP-A resulted in a dose-dependent reduction of the infectivity of the viruses to cells. Removal of the carbohydrate moiety of SP-A by N-glycosidase F or cleavage of its sialic acid residues by neuraminidase prevented the interactions of SP-A with the viruses. It is concluded that SP-A binds to influenza A viruses via its sialic acid residues and, thereby, neutralizes the virus.


Influenza A virus/metabolism , Proteolipids/metabolism , Proteolipids/pharmacology , Pulmonary Surfactants/metabolism , Pulmonary Surfactants/pharmacology , Animals , Antibodies, Monoclonal , Antibodies, Viral , Cells, Cultured , Dose-Response Relationship, Drug , Fluorescein-5-isothiocyanate , Fluorometry , Humans , Immunoenzyme Techniques , Influenza A virus/growth & development , Oligosaccharides/pharmacology , Protein Binding/drug effects , Pulmonary Surfactant-Associated Protein A , Pulmonary Surfactant-Associated Proteins , Virus Replication/drug effects
13.
J Clin Microbiol ; 32(4): 987-90, 1994 Apr.
Article En | MEDLINE | ID: mdl-8027355

A neutralization enzyme immunoassay (N-EIA) was developed for the detection of antibody titer rises in sera of patients infected with influenza A (H3N2) virus. In this N-EIA, a selected strain of influenza A (H3N2) virus was added to monolayers of LLC-MK2 cells in microtiter plates. After 24 h, the replicated virus could be demonstrated with a virus-specific enzyme-labeled monoclonal antibody. Preincubation of the influenza virus with convalescent-phase sera of patients infected with influenza A (H3N2) virus resulted 1 day later in decreased absorbance values that could be used for calculation of neutralization titers. From use of paired serum samples from 10 patients with a history of flu-like symptoms, the results obtained with N-EIA correlated well (r = 0.83) with those of the standard hemagglutination inhibition test.


Immunoenzyme Techniques , Influenza A virus/immunology , Influenza, Human/diagnosis , Neutralization Tests/methods , Animals , Antibodies, Monoclonal , Antibodies, Viral/blood , Antigens, Viral , Cell Line , Evaluation Studies as Topic , Hemagglutination Inhibition Tests , Humans , Influenza A virus/physiology , Influenza, Human/immunology , Mice , Serologic Tests/methods , Virus Cultivation , Virus Replication
14.
Eur J Clin Microbiol Infect Dis ; 12(2): 118-21, 1993 Feb.
Article En | MEDLINE | ID: mdl-8500479

A 13-year-old Moroccan boy in The Netherlands developed fever and a lesion resembling ecthyma gangrenosum on the abdomen during cytostatic drug treatment for a lymphoblastic B-cell lymphoma. Scytalidium dimidiatum was cultured from blood and the abdominal skin lesion. The patient was successfully treated with amphotericin B. The fungus Scytalidium dimidiatum is a fairly common plant pathogen in tropical and subtropical countries and is known to cause dermatomycoses in humans in these areas. This case demonstrates that it is necessary to be aware that immigrants from these areas can import their own fungal flora, some members of which may cause life-threatening disease in the case of patients with immune suppression.


Immunocompromised Host , Lymphoma, B-Cell/complications , Mitosporic Fungi/isolation & purification , Mycoses/microbiology , Neutropenia/complications , Adolescent , Amikacin/therapeutic use , Amphotericin B/therapeutic use , Ceftazidime/therapeutic use , Drug Therapy, Combination , Humans , Male , Morocco/ethnology , Mycoses/drug therapy , Mycoses/ethnology , Netherlands , Vancomycin/therapeutic use
...